Intrinsic Semiconductor Technologies is established to developed silicon-oxide based RRAM technologies. Intrinsic's technology is fully air stable and inherently CMOS compatible. Intrinsic's core technology can be configured as non-volatile memory, multilevel memory, hardware acceleration for Machine Learning, and neuromorphic devices.
Bramble Energy Ltd. is a London-based company that specializes in the design, development, and manufacture of printed circuit board fuel cells (PCBFCs). Leveraging its expertise in the high-volume printed circuit board industry, the company produces a range of fuel cell products, including 20 W, 500 W, and 5 kW PCBFC stacks, as well as custom-designed solutions. Bramble Energy aims to supply gigawatts of fuel cell hardware, positioning itself as a leader in the energy technology sector. Its innovative approach caters to various applications across the stationary, portable, automotive, and mobility sectors. Founded in 2015, Bramble Energy is focused on delivering high-performance and cost-effective fuel cell solutions.
Carbon Re specializes in the decarbonization of high-emission industries, focusing on sectors such as cement, steel, metals, bulk chemicals, glass, paper, and ceramics. The company has developed a cloud-based Foundation Platform that integrates advanced continuous improvement techniques with artificial intelligence. This platform aims to enhance operational efficiencies while significantly reducing greenhouse gas emissions in manufacturing processes. By leveraging this technology, Carbon Re enables its clients to achieve reductions in emissions of up to 20%, resulting in substantial savings on electricity, fuel, and carbon costs for each plant annually.
Apollo Therapeutics is a collaborative initiative involving three prominent UK universities—Imperial College London, University College London, and the University of Cambridge—and three major pharmaceutical companies: AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation. The organization focuses on funding and developing novel therapeutics derived from leading British academic research, facilitating their progression toward clinical application. With a model that provides rapid access to resources, Apollo Therapeutics champions innovative research and enhances collaboration between academia and industry. Its team of experienced scientists, who have a strong track record in therapeutic delivery, works closely with academic researchers and industry partners to tailor projects for optimal success. The overarching goal of Apollo Therapeutics is to advance future therapies that significantly improve patient treatments and outcomes.
Intrinsic Semiconductor Technologies is established to developed silicon-oxide based RRAM technologies. Intrinsic's technology is fully air stable and inherently CMOS compatible. Intrinsic's core technology can be configured as non-volatile memory, multilevel memory, hardware acceleration for Machine Learning, and neuromorphic devices.
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.
Nozzle.ai is an eCommerce and advertising optimization platform focused on enhancing sales for online sellers, particularly on Amazon. The company provides a suite of services, including marketplace audits, advertisement optimization, and consulting. Utilizing data science, Nozzle.ai analyzes customer buying patterns to deliver insights on key metrics such as customer repeat order rates, lifetime value, and customer acquisition costs. This data-driven approach enables online sellers and agencies to improve their advertising strategies, ultimately increasing sales and revenue. Founded in 2014 and headquartered in London, Nozzle.ai operates under the umbrella of Beeswax, Inc. after rebranding from MediaGamma Limited in May 2020. The company's offerings also include artificial intelligence consultancy, machine learning operations, and various support services for setting up and managing advertising campaigns.
Bramble Energy Ltd. is a London-based company that specializes in the design, development, and manufacture of printed circuit board fuel cells (PCBFCs). Leveraging its expertise in the high-volume printed circuit board industry, the company produces a range of fuel cell products, including 20 W, 500 W, and 5 kW PCBFC stacks, as well as custom-designed solutions. Bramble Energy aims to supply gigawatts of fuel cell hardware, positioning itself as a leader in the energy technology sector. Its innovative approach caters to various applications across the stationary, portable, automotive, and mobility sectors. Founded in 2015, Bramble Energy is focused on delivering high-performance and cost-effective fuel cell solutions.
Humanloop Ltd is a London-based company that specializes in artificial intelligence, focusing on data labeling and model training to enhance the efficiency of human workforce scaling. Established in 2020, the company aims to revolutionize the training of AI systems by significantly reducing the amount of human input required, achieving improvements in performance with ten times less training than conventional methods. Humanloop's platform and tools are designed to facilitate advancements in machine learning and natural language processing research, making it a key player in the AI sector.
AstronauTx
Venture Round in 2020
AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.
Astroscreen protects brands and defends democracy from harmful social media manipulation campaigns also known as astroturfing.
Phasecraft Limited is a UK-based company founded in 2018 that specializes in developing quantum software for quantum information processors, including intermediate-scale devices and quantum computers. The company focuses on creating algorithms that enable clients to address complex challenges in various industries, such as discovering new catalysts and optimizing key industrial processes. By leveraging its software, Phasecraft aims to enhance the practical application of quantum computing, allowing clients to explore innovative quantum materials and improve the efficiency of technologies like batteries and solar cells.
Context Scout aims to revolutionise the way every person uses the web. We're building the next generation in web assistance technology - a content-aware browser that doesn’t just show you webpages, but one that reads and comprehends the content, understands what you are trying to do online (making sense of tasks across multiple tabs), and helps you get it done. The world's first web browser chatbot - Your digital assistant for getting anything done online ** Under Development ** Soon we will be able to assist you with: * Online Shopping Scout will find alternative prices, discounts, reviews and summarise your shopping in time for your purchase decision. * Event Planning Scout will check your calendar to see if you're available and plan out your route to the event. * And everything else Need to know how many calories are in the recipe you're looking at? Need the perfect gif for your tweet? Want to find out what people are saying on social m
KIT-AR Ltd designs and develops an integrated industrial augmented reality system for enhancing manufacturing productivity. The company provides all the information needed to assemble and engineer products to reduce unplanned downtime caused by human error. It offers KIT-ASSIST, that offers specialist knowledge and details directly to a heads up display; KIT-SMART, a set of intelligent modules that sense the working environment and monitor worker activity; KIT-BUILD, which allows users to manage work instructions according to the operations; and KIT-INSIGHT, which offers productivity and efficiency insights. KIT-AR Ltd was founded in 2018 and is based in London, United Kingdom.
Hazy Limited is a London-based company that specializes in automatic data anonymization using artificial intelligence. Incorporated in 2017, Hazy develops a platform that generates synthetic data, which retains the statistical properties of real datasets while ensuring the privacy and confidentiality of personal information. This innovative approach allows businesses to share and utilize data for analytics and innovation without the risks associated with compliance and security breaches. By capturing patterns from raw data, Hazy creates entirely synthetic datasets that provide the statistical value of the original data, enabling data-centric organizations to unlock their data potential more safely and efficiently. Hazy is recognized as a spin-out from University College London and has garnered backing from prominent partners such as Microsoft and Nationwide.
Freeline Therapeutics is a clinical-stage biotechnology company focused on developing liver-directed gene therapies for bleeding disorders and other diseases. Based in Stevenage, United Kingdom, Freeline's lead product candidate, FLT180a, is undergoing Phase 1/2 clinical trials aimed at treating moderate to severe hemophilia B. The company's pipeline also includes FLT190, which is in dose-escalating Phase 1/2 trials for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A. Freeline utilizes a next-generation proprietary adeno-associated virus (AAV) vector platform, enhancing its potential for systemic gene therapy applications. Since its founding in 2015, the company has been dedicated to advancing innovative treatments in the field of gene therapy.
Glialign specializes in regenerative technologies aimed at enhancing peripheral nerve repair. The company is developing a novel cell therapy that serves as a living nerve growth guide, designed to replace traditional nerve grafts, which often require harvesting nerves from other body parts. Current treatments for peripheral nerve injuries are only effective in less than half of the cases, highlighting the need for more reliable solutions. Glialign's approach provides an off-the-shelf alternative, enabling healthcare providers to facilitate nerve regeneration and improve functional recovery for patients suffering from nerve injuries.
In a data-rich world where AI is a ‘must have’, MediaGamma is a team of world-class AI experts who help digital professionals understand digital user behaviour. The team is a spin-out from a premier global centre of computing science academic excellence, University College London. Their domain expertise means that they can translate business opportunities into solutions with tangible results, using the most advanced machine learning techniques such as predictive, self-learning algorithms that make decisions in real time.
Hazy Limited is a London-based company that specializes in automatic data anonymization using artificial intelligence. Incorporated in 2017, Hazy develops a platform that generates synthetic data, which retains the statistical properties of real datasets while ensuring the privacy and confidentiality of personal information. This innovative approach allows businesses to share and utilize data for analytics and innovation without the risks associated with compliance and security breaches. By capturing patterns from raw data, Hazy creates entirely synthetic datasets that provide the statistical value of the original data, enabling data-centric organizations to unlock their data potential more safely and efficiently. Hazy is recognized as a spin-out from University College London and has garnered backing from prominent partners such as Microsoft and Nationwide.
Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. Operating in the United Kingdom, European Union, and the United States, Orchard employs an autologous ex vivo gene therapy approach to transform patients’ hematopoietic stem cells into gene-modified products for treatment through a single administration. Its portfolio includes Strimvelis, the first approved gene therapy for adenosine deaminase-severe combined immunodeficiency (ADA-SCID), along with several products in clinical development targeting metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has a robust preclinical pipeline addressing various mucopolysaccharidosis types. Orchard collaborates with leading institutions in gene therapy, enhancing its research capabilities and clinical programs. Founded in 2015, Orchard Therapeutics continues to demonstrate a commitment to transforming the lives of patients through its advanced therapies.
MeiraGTx is a clinical-stage gene therapy company dedicated to developing and commercializing innovative gene therapy products aimed at transforming the lives of patients with acquired and inherited disorders. The company has a diverse pipeline that includes several ongoing clinical programs focused primarily on treating conditions related to the eye, salivary gland, and central nervous system. Key product candidates include AAV-CNGB3, AAV-CNGA3, and AAV-RPGR, among others. MeiraGTx operates in the United States, the United Kingdom, and the European Union, leveraging its expertise in viral vector design and gene therapy manufacturing. With a portfolio approach to technology development, the company plans to expand its focus to include additional gene therapy treatments for various serious diseases in the future.
Bloomsbury AI Limited was a London-based company that specialized in developing a Software as a Service (SaaS) platform for creating text-understanding computer applications. Founded in April 2015 by a team that included Guillaume Bouchard and Sebastian Riedel, the company's technology utilized artificial intelligence to read documents and learn from user interactions, allowing it to perform tasks similarly to how human apprentices acquire skills. This platform aimed to automate expertise through written dialogue, enabling users to efficiently execute repetitive tasks and streamline their workflows. Although Bloomsbury AI was once a subsidiary of Facebook, it ultimately went into liquidation.
Freeline Therapeutics is a clinical-stage biotechnology company focused on developing liver-directed gene therapies for bleeding disorders and other diseases. Based in Stevenage, United Kingdom, Freeline's lead product candidate, FLT180a, is undergoing Phase 1/2 clinical trials aimed at treating moderate to severe hemophilia B. The company's pipeline also includes FLT190, which is in dose-escalating Phase 1/2 trials for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A. Freeline utilizes a next-generation proprietary adeno-associated virus (AAV) vector platform, enhancing its potential for systemic gene therapy applications. Since its founding in 2015, the company has been dedicated to advancing innovative treatments in the field of gene therapy.
Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. Operating in the United Kingdom, European Union, and the United States, Orchard employs an autologous ex vivo gene therapy approach to transform patients’ hematopoietic stem cells into gene-modified products for treatment through a single administration. Its portfolio includes Strimvelis, the first approved gene therapy for adenosine deaminase-severe combined immunodeficiency (ADA-SCID), along with several products in clinical development targeting metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has a robust preclinical pipeline addressing various mucopolysaccharidosis types. Orchard collaborates with leading institutions in gene therapy, enhancing its research capabilities and clinical programs. Founded in 2015, Orchard Therapeutics continues to demonstrate a commitment to transforming the lives of patients through its advanced therapies.